STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues

Versant Ventures, Eli Lilly, and a handful of other investors will pour $100 million into a new startup devoted to solving a thorny gene therapy challenge.
Sourcing & attribution. Newseze provides AI-curated summaries, narrative framing, and editorial analysis. The underlying reporting was contributed by STAT News; tap “Open original source” above to read their full reporting and support the contributing newsroom directly.
Newseze's algorithm reads the story and answers your question — calmly, factually, with source attribution. No comments, no flame wars — just answers.
No questions yet. Be the first.
Answers reflect Newseze's editorial framework applied under fair use (17 U.S.C. § 107). Not financial, legal, medical, or tax advice. Hate speech and racial slurs are blocked.
Related stories

Why it mattersApple and OpenEvidence are launching a study based around an experimental AI-powered health chat app, hinting at possible new directions for both companies.